Marathon Asset Management
Marathon Asset Management, LP is an employee-owned investment firm based in New York City, with additional offices in Tokyo, London, and Singapore. Founded in 1998, the firm manages approximately $11 billion in capital and focuses on opportunistic investing in credit and fixed income markets globally. Marathon provides a range of services, including managing hedge funds, structured finance programs, and real estate investments. The firm employs a bottom-up approach, utilizing fundamental and technical analysis to construct its investment portfolios. It caters to various clients, including investment companies, government entities, insurance companies, and other investment advisers. The firm specializes in credit strategies, managing a family of investment programs that encompass hedge funds, managed accounts, and collateralized loan obligations, while investing across multiple sectors such as media, financial services, and healthcare.
Theratechnologies Inc., a biopharmaceutical company, engages in the discovery of therapeutic products for commercialization. The company's proprietary technologies include Long Acting Peptides, a peptide stabilization technology that increases the target protein's resistance to enzymatic degradation. Its lead product is tesamorelin, which completed its phase III clinical trial for the treatment of HIV-associated lipodystrophy and is in phase II clinical trials for the treatment of mild cognitive impairment and growth hormone deficient abdominal obesity. The company also develops Acute kidney injury, a preclinical stage product. It has a license agreement with PDC Biotech GmbH to use the antagonists of the prostaglandin F2a receptor in pre-term labor and primary dysmenorrheal; and OctoPlus N.V. to develop and commercialize GLP-1 portfolio of analogues. The company also has a collaboration and licensing agreement with EMD Serono, Inc. for the treatment of excess abdominal fat in HIV-infected patients with lipodystrophy. The company was founded in 1993 and is headquartered in Montreal, Canada.
Acer Therapeutics Inc. is a pharmaceutical company dedicated to the acquisition, development, and commercialization of therapies for serious rare and life-threatening diseases with significant unmet medical needs. The company's clinical pipeline features several candidates, including EDSIVO, aimed at treating vascular Ehlers-Danlos Syndrome in patients with a confirmed type III collagen mutation, and ACER-001, a formulation of sodium phenylbutyrate designed for various inborn errors of metabolism, such as urea cycle disorders and maple syrup urine disease. Additionally, Acer is developing osanetant for the treatment of induced Vasomotor Symptoms and emetine hydrochloride as a potential therapeutic option for COVID-19 patients, through a collaboration with the National Center for Advancing Translational Sciences. Founded in 2013, Acer Therapeutics is headquartered in Newton, Massachusetts.
BigBear.ai is a decision dominance serving the national defense and intelligence communities. The Company delivers high-end capabilities across the data and digital spectrum to deliver information superiority and decision support. BigBear.ai provides a comprehensive suite of solutions including artificial intelligence and machine learning, data science, advanced analytics, offensive and defensive cyber, data management, cloud solutions, digital engineering, and systems integration.
Avenger Flight Group, LLC is an aviation training company that specializes in commercial aviation simulation and training services. Founded in 2012 and headquartered in Fort Lauderdale, Florida, the company operates additional training facilities in Las Vegas, Nevada; Mexico City, Mexico; and Fort Worth, Texas. Avenger Flight Group employs state-of-the-art simulators to deliver training to both domestic and international airlines, enhancing the skills of pilots and trainers. In addition to simulation training, the company offers classroom instruction, ensuring comprehensive educational support for aviation professionals.
Private Equity Round in 2021
Dermavant Sciences Ltd. is a clinical-stage biopharmaceutical company specializing in medical dermatology therapeutics. The company's lead product candidate, Tapinarof, is a topical cream undergoing Phase III clinical trials for the treatment of psoriasis and atopic dermatitis. Dermavant's pipeline includes additional candidates in various stages of development, such as Cerdulatinib, which targets vitiligo and other inflammatory skin conditions, and Oxybutynin/Pilocarpine, an oral therapy for primary focal hyperhidrosis. Preclinical candidates include DMVT-503, aimed at treating acne vulgaris, and DMVT-501, a potential treatment for atopic dermatitis. Dermavant Sciences has established licensing agreements with several pharmaceutical companies and operates as a subsidiary of Roivant Sciences Ltd. The company, originally known as Roivant Dermatology Ltd., rebranded in June 2016 and is based in London, United Kingdom.
Private Equity Round in 2021
Healogics, headquartered in Jacksonville, Florida, is the largest provider of advanced wound care services in the United States. The company manages over 500 Wound Care Centers nationwide and serves nearly 200,000 patients annually through a comprehensive network that includes partner hospitals and academic medical centers. Healogics focuses on treating chronic wounds, particularly in underserved populations, by employing an evidence-based approach to wound healing. The organization aims to advance the science of wound medicine and continuously improve treatment options for patients suffering from conditions such as diabetes, cancer, and vascular disease.
Europcar is the largest car rental company in Europe and currently has 2825 locations in 143 different countries. Europcar offices in Germany, France, Italy, Spain, Portugal and the United Kingdom are run centrally by Europcar in France, while all other countries are franchisees.
ADMA Biologics, Inc. is a biopharmaceutical company focused on developing, manufacturing, and marketing specialty plasma-derived biologics aimed at treating immune deficiencies and infectious diseases in the United States. The company's product portfolio includes BIVIGAM and ASCENIV, both intravenous immune globulin products indicated for primary humoral immunodeficiency, as well as Nabi-HB, which treats acute exposure to Hepatitis B. ADMA also has a pipeline of therapeutics targeting infections such as S. pneumonia. To support its production, ADMA operates FDA-licensed source plasma collection facilities, known as ADMA BioCenters, which supply plasma for its products. The company distributes its offerings through independent distributors, sales agents, and specialty pharmacies. Founded in 2004 and headquartered in Ramsey, New Jersey, ADMA Biologics is dedicated to serving niche patient populations, particularly those who are immune-compromised due to underlying conditions or medical treatments.
Sipex Corporation
Venture Round in 2006
Sipex Corporation engages in the design, manufacture, and marketing of analog integrated circuits (ICs). It offers power management products, including white LED drivers, DC/DC regulators, and controllers to regulate, control, monitor, or provide the reference voltage for a system or portion of a system. The company also provides interface products that facilitate the transfer of digital signals between or within electronic systems, as well as ensure connectivity between networks, computers, and digital peripherals and consumer portable devices that connect to them. In addition, it offers optical storage products, including photo-detector ICs, advanced power control ICs, and laser diode drivers.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.